.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,928,239

« Back to Dashboard

Details for Patent: 7,928,239

Title:Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
Inventor(s): Dumas; Jacques (Orange, CT), Riedl; Bernd (Wuppertal, DE), Khire; Uday (Hamden, CT), Wood; Jill E. (Hamden, CT), Sibley; Robert N. (North Haven, CT), Monahan; Mary-Katherine (Hamden, CT), Renick; Joel (Milford, CT), Gunn; David E. (Hamden, CT), Lowinger; Timothy B. (Nishinomiya, JP), Scott; William J. (Guilford, CT), Smith; Roger A. (Madison, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Filing Date:Feb 07, 2001
Application Number:09/777,920
Claims:1. A compound of Formula I A-D-B (I) or a pharmaceutically acceptable salt thereof, wherein: D is --NH--C(O)--NH--, A is of the formula: -L-(M-L.sup.1).sub.q, where L is substituted or unsubstituted phenyl bound directly to D, L.sup.1 is phenyl substituted by --C(O)R.sub.x, or pyridinyl substituted by --C(O)R.sub.x, M is oxygen, q is 1 and B is a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinolinyl group or a substituted or unsubstituted isoquinolinyl group, where B is substituted, L is substituted or L.sup.1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3; R.sub.x, is NR.sub.aR.sub.b where R.sub.a and R.sub.b are, a) independently hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.3-10 cycloalkyl, C.sub.2-10 alkenyl, C.sub.1-10 alkenoyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted C.sub.1-10 alkyl, substituted C.sub.3-10 cycloalkyl, substituted phenyl, substituted pyridinyl, substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where R.sub.a and R.sub.b are a substituted group, they are substituted by halogen up to per halo, hydroxy, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, C.sub.3-10 cycloalkyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, halo-substituted C.sub.1-6 alkyl up to per halo alkyl, halo-substituted phenyl up to per halo phenyl, halo-substituted pyridinyl, up to per halo pyridinyl, halo-substituted morpholinyl, up to per halo morpholinyl, halo-substituted piperidinyl, up to per halo piperidinyl, halo-substituted pyrrolidinyl, up to per halo pyrrolidinyl, or halo-substituted tetrahydrofuryl up to per halo tetrahydrofuryl, each W is independently --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7, --C(O)--R.sup.7, --NO.sub.2, --OR', --SR.sup.7, --NR.sup.7R.sup.7, --NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10 alkenyl, C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, or tetrahydrofuryl, substituted C.sub.1-C.sub.10 alkyl, substituted C.sub.1-C.sub.10 alkoxy, substituted C.sub.2-C.sub.10 alkenyl, substituted C.sub.1-C.sub.10 alkenoyl, substituted C.sub.3-C.sub.10 cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where W is a substituted group, it is substituted by one or more substituents which are each, independently, --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7, --OR', --SR', --NR.sup.7R.sup.7, --NO.sub.2, --NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 or halogen, each R.sup.7 is independently H, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10 alkenyl, C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl, phenyl or pyridinyl up to per-halosubstituted C.sub.1-C.sub.10 alkyl, up to per-halosubstituted C.sub.3-C.sub.10 cycloalkyl or up to per-halo substituted phenyl.

2. A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

3. A compound of claim 1 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or substituted isoquinolinyl group substituted 1 to 3 times by one or more substituents which are each, independently, --CN, halogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, --OH, up to per halo substituted C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.1-C.sub.10 alkoxy or phenyl substituted by halogen up to per halo.

4. A compound of claim 1 wherein L.sup.1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen, C.sub.1-C.sub.10 alkoxy or up to per halo substituted C.sub.1-C.sub.10 alkoxy.

5. A compound of claim 1 wherein L.sup.1 is substituted only by --C(O)R.sub.x.

6. A compound of claim 1 wherein L.sup.1 is substituted by --C(O)R.sub.x wherein R.sub.x is NR.sub.aR.sub.b and R.sub.a and R.sub.b are independently hydrogen or C.sub.1-C.sub.10 alkyl.

7. A compound of claim 1 which is a pharmaceutically acceptable salt of a compound of formula I which is a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

8. A pharmaceutical composition comprising a compound of Formula I of claim 1 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

9. A compound which is ##STR00197## ##STR00198## or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound which is ##STR00199## ##STR00200## or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

11. A method for treating colorectal cancer in a host, comprising administering to a host in need thereof an effective amount of a compound which is ##STR00201## ##STR00202## or a pharmaceutically acceptable salt thereof.

12. A compound of Formula I: A-D-B (I) or a pharmaceutically acceptable salt thereof, wherein D is --NH--C(O)--NH--, A is of the formula: -L-(M-L.sup.1).sub.q, where L is phenyl bound directly to D, L.sup.1 is pyridinyl, M is oxygen and q is 1; and B is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group, wherein L.sup.1 is substituted by --C(O)R.sub.x, R.sub.x is NR.sub.aR.sub.b where R.sub.a and R.sub.b are independently hydrogen or C.sub.1-C.sub.10 alkyl, where B is substituted, L is substituted or L.sup.1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3; wherein each W is independently --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7, --C(O)--R.sup.7, --NO.sub.2, --OW, --SR.sup.7, --NR.sup.7R.sup.7, --NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10 alkenyl, C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted C.sub.1-C.sub.10 alkyl, substituted C.sub.1-C.sub.10 alkoxy, substituted C.sub.2-C.sub.10 alkenyl, substituted C.sub.1-C.sub.10 alkenoyl, substituted C.sub.3-C.sub.10 cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where W is a substituted group, it is substituted by one or more substituents which are each, independently, --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7, --OW, --SR.sup.7, --NR.sup.7R.sup.7, --NO.sub.2, --NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 or halogen.

13. A compound as in claim 12 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

14. A compound of claim 12 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or isoquinolinyl group substituted 1 to 3 times by 1 or more substituents which are each independently --CN, halogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, --OH, up to per halo substituted C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.1-C.sub.10 alkoxy or phenyl substituted by halogen up to per halo.

15. A compound of claim 12 wherein L.sup.1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen, C.sub.1-C.sub.10 alkoxy or up to per halo substituted C.sub.1-C.sub.10 alkoxy.

16. A compound as in claim 12 wherein substituents for B and L and additional substituents for L.sup.1, are each, independently, C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.1-C.sub.10 alkyl, CN, OH, halogen, C.sub.1-C.sub.10 alkoxy or up to per halo substituted C.sub.1-C.sub.10 alkoxy.

17. A compound of claim 12 which is a pharmaceutically acceptable salt of a compound of formula I which is a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

18. A pharmaceutical composition comprising a compound of claim 12 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc